XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1
REVENUE RECOGNITION AND RELATED ALLOWANCES - Disaggregation (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Disaggregation of Revenue [Line Items]        
Total net revenues $ 138,040 $ 116,547 $ 275,470 $ 223,333
Sales of generic pharmaceutical products        
Disaggregation of Revenue [Line Items]        
Total net revenues 73,964 63,317 144,181 127,030
Sales of established brand pharmaceutical products, royalties, and other pharmaceutical services        
Disaggregation of Revenue [Line Items]        
Total net revenues 14,883 28,926 45,159 55,669
Sales of rare disease pharmaceutical products        
Disaggregation of Revenue [Line Items]        
Total net revenues $ 49,193 $ 24,304 $ 86,130 $ 40,634